Incyte
- Country
- 🇺🇸United States
- Ownership
- -
- Employees
- 2.5K
- Market Cap
- $12.6B
- Introduction
Incyte Corp. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of proprietary therapeutics. It focuses on hematology and oncology, and inflammation and autoimmunity therapeutic areas. The company was founded in April 1991 and is headquartered in Wilmington, DE.
TRuE AD2 - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 618
- Registration Number
- NCT03745651
- Locations
- 🇺🇸
Jubilee Clinical Research - BTC - PPDS, Las Vegas, Nevada, United States
🇺🇸Center For Dermatology Cosmetic And Laser Surgery, Fremont, California, United States
🇺🇸Synexus Clinical Research US Inc. Santa Rosa, Santa Rosa, California, United States
Topical Ruxolitinib Evaluation in Atopic Dermatitis Study 1 (TRuE AD1) - An Efficacy and Safety Study of Ruxolitinib Cream in Adolescents and Adults With Atopic Dermatitis
- First Posted Date
- 2018-11-19
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 631
- Registration Number
- NCT03745638
- Locations
- 🇺🇸
First OC Dermatology, Fountain Valley, California, United States
🇺🇸Dermatology Specialists Inc, Oceanside, California, United States
🇺🇸Integrated Research Group Inc., Riverside, California, United States
Safety and Efficacy of Itacitinib in Combination With Corticosteroids for Treatment of Graft-Versus-Host Disease in Pediatric Subjects
- Conditions
- Interventions
- First Posted Date
- 2018-10-26
- Last Posted Date
- 2023-02-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 2
- Registration Number
- NCT03721965
- Locations
- 🇺🇸
University of Minnesota Medical Center, Minneapolis, Minnesota, United States
🇺🇸Duke University Medical Center, Durham, North Carolina, United States
🇺🇸University Hospitals Cleveland Medical Center - Rainbow Babies and Children's Hospital, Cleveland, Ohio, United States
A Safety and Tolerability Study of INCB053914 in Combination With INCB050465 in Diffuse Large B-Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2018-09-28
- Last Posted Date
- 2020-11-10
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 9
- Registration Number
- NCT03688152
- Locations
- 🇺🇸
UCLA Healthcare Hematology-Oncology, Santa Monica, California, United States
🇺🇸University of Arizona Cancer Center, Tucson, Arizona, United States
🇺🇸Clinical Research Alliance, Lake Success, New York, United States
A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203)
- First Posted Date
- 2018-09-20
- Last Posted Date
- 2023-07-21
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 121
- Registration Number
- NCT03679767
- Locations
- 🇺🇸
Texas Oncology - Waco, Waco, Texas, United States
🇦🇹LKH Graz, Graz, Austria
🇺🇸California Cancer Associates for Research and Excellence, Inc., San Marcos, California, United States
A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma
- Conditions
- Interventions
- First Posted Date
- 2018-09-04
- Last Posted Date
- 2024-07-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 167
- Registration Number
- NCT03656536
- Locations
- 🇺🇸
Parkview Research Center, Fort Wayne, Indiana, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
🇺🇸University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
A Safety and Tolerability Study of INCAGN02390 in Select Advanced Malignancies
- First Posted Date
- 2018-08-29
- Last Posted Date
- 2021-11-15
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 40
- Registration Number
- NCT03652077
- Locations
- 🇺🇸
The Angeles Clinical and Research Institute, Los Angeles, California, United States
🇺🇸Hackensack Medical Center, Hackensack, New Jersey, United States
🇺🇸University of Mississippi, Jackson, Mississippi, United States
A Study to Evaluate the Safety and Efficacy of Itacitinib in Moderate to Severe Ulcerative Colitis
- Conditions
- Interventions
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2019-12-06
- Lead Sponsor
- Incyte Corporation
- Registration Number
- NCT03627052
A Study of INCB050465 in Primary Sjögren's Syndrome
- First Posted Date
- 2018-08-13
- Last Posted Date
- 2021-08-13
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 10
- Registration Number
- NCT03627065
- Locations
- 🇺🇸
The Center for Rheumatology and Bone Research, Wheaton, Maryland, United States
🇺🇸North Georgia Rheumatology Group, Lawrenceville, Georgia, United States
🇺🇸Advanced Pharma CR, Miami, Florida, United States
A Placebo-Controlled Study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa
- First Posted Date
- 2018-07-31
- Last Posted Date
- 2022-09-26
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 35
- Registration Number
- NCT03607487
- Locations
- 🇩🇪
Investigative Site, Lübeck, Schleswig-Holstein, Germany
🇨🇦Investigative Site 009, Markham, Ontario, Canada
🇨🇦Investigative Site 008, Richmond Hill, Ontario, Canada